Reuters logo
BRIEF-UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use
September 21, 2017 / 5:32 PM / a month ago

BRIEF-UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use

Sept 21 (Reuters) - UCB SA:

* ANTI-EPILEPTIC DRUG VIMPAT (LACOSAMIDE) RECEIVES EU APPROVAL FOR PAEDIATRIC USE

* VIMPAT APPROVED FOR MONOTHERAPY AND ADJUNCTIVE THERAPY OF PARTIAL-ONSET (FOCAL) SEIZURES IN CHILDREN AGED 4 YEARS AND OLDER Source text: bit.ly/2wJZpXB Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below